NVAX•benzinga•
Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Summary
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 3, 2025 by benzinga